Bangalore, India — Leucine Rich Bio Pvt. Ltd., Bangalore based bioinformatics driven company has announced alliance partnership with New Delhi based NextGen Life sciences for promoting its products and services in the Indian market.

Leucine Rich Bio Pvt. Ltd (LRB) operates in a niche domain of NGS data analysis and is involved in providing ‘software as a service’ utilizing its proprietary in- house developed Human Genome Analysis, Interpretation & Reporting platform called AGIS (Advanced Genome Interpretation Suite). AGIS uses an intuitive ranking system to identify clinically relevant variants. AGIS annotates variants from multiple knowledge bases including Leucine Rich Bio’s Human Genome Variation Database (LRB-HGVD). LRB plans to launch AGIS for clinics and diagnostics wherein it would cater to the developing field of ‘personalized genomics’ thereby providing the clinician with actionable mutation analysis. The clinical report contains relevant information that is needed to make clinical decisions. Clinical reports are tailored to provide highly ranked disease-causing or clinically pathogenic variants. The report will also contain variants related to pharmacogenomics.

Leucine Rich Bio Pvt Ltd also provides NGS data analysis service to researchers worldwide using its proprietary platforms. Currently, LRB is involved in providing NGS data analysis service pertaining to whole genome, exome, Transcriptome and small RNA sequencing.

According to the MoU signed between LRB and NextGen Life sciences, NextGen Life Sciences which handles multinational companies like Thermo Fisher, DSS Takara Bio and Germany based HighQu GmbH in its portfolio, would provide its market depth and field penetration in the Indian market to promote LRB’s products and services. Speaking on this occasion Dr Debojyoti Dhar, Director (Business development and Innovation), LRB opines “getting NextGen Life sciences on board our journey at this stage is very important for LRB and we feel that our two companies can complement each other well and we look forward to a mutually rewarding association”.

Dr Nagma Abbasi, MD of NextGen Life Sciences also reverberates the same sentiment and says “Our rich experience in Indian Life Sciences market makes us confident that NextGen Life Sciences will successfully integrate LRB products and services in India and will be growing business further together. With the addition of LRB, we are in an even stronger position to help our customers to achieve their goals for innovation and productivity. Our combine offerings will provide cutting edge technologies to accelerate Life Sciences Research and improve human health. ”